PharmaFocus Today – Page 51 – media

The 2025 National Drug Inspection Work Conference was held

The reporter learned from the National Drug Administration that on February 25, the 2025 National Drug Inspection Work Conference was held in Nanchang. The meeting summarized the results of the 2024 drug inspection work, deeply analyzed the current situation, exchanged inspection work experience, and deployed key tasks for 2025. The meeting required that drug regulatory departments and drug testing institutions at all levels strictly implement the “four strictest” requirements, follow the working ideas of “being political, strengthening supervision, ensuring safety, promoting development, and benefiting people’s livelihood”, and jointly carry out drug inspection work, and play an important role in discovering and eliminating risks and hidden dangers, continuously improving drug quality, and ensuring the safety of public drug use. It is necessary to strengthen political guidance, strictly implement responsibilities, firmly establish risk awareness, adhere to problem orientation, strengthen capacity building, improve work mechanisms, coordinate annual drug inspection work, and effectively improve ...
- Source: drugdu
- 153
- March 3, 2025
Two more people under China Pharmaceutical Group were investigated

On February 28, Wang Zhiguang, member of the Party Committee and deputy general manager of China Pharmaceutical and Health Products Co., Ltd. (hereinafter referred to as China Pharmaceutical and Health Products), was suspected of serious violations of discipline and law. He is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of General Technology Group and the Supervision Committee of Xingshan County, Yichang City, Hubei Province; Guo Cui, former manager of the administrative department of Hubei General Pharmaceutical Co., Ltd. (hereinafter referred to as Hubei General), was suspected of serious violations of discipline and law. He is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of General Technology Group and the Supervision Committee of Yiting District, Yichang City, Hubei Province. According to Qichacha, China Pharmaceutical and Health Products is a wholly-owned subsidiary of China Pharmaceutical (600056.SH), and China Pharmaceutical ...
- Source: drugdu
- 119
- March 3, 2025
China’s first public REITs fund for pharmaceuticals, China Universal Pharmaceutical REIT, was successfully listed

February 27, China Universal Pharmaceutical REIT (fund code “508084”), the first public REIT for pharmaceutical warehousing and logistics in China, which has attracted much attention from the market, was officially listed on the Shanghai Stock Exchange on February 27, 2025. As the first public REIT in the pharmaceutical industry, the successful issuance of China Universal Pharmaceutical REIT marks a breakthrough in the professional segmentation of project asset categories in my country’s public REITs market, and reflects the innovative practice of the capital market in serving the high-quality development of the real economy. The primary and secondary markets of public REITs continue to be hot China Universal Pharmaceutical REIT, which was completed on February 10, had a subscription multiple of 1,192 times by public investors, setting a new record for public REITs. As a latecomer, Jiuzhoutong Pharmaceutical REIT broke the record of 813.44 times set by the recently listed Guotai Junan ...
- Source: drugdu
- 159
- March 3, 2025
Corning Oncology Pharmaceuticals’ stock price surged after being removed from the Hang Seng Composite Index

At the close of February 27, Corning Oncology Pharmaceuticals-B (09966) closed at HK$6.08, up 22.33%, with a turnover rate of 3.63%, a trading volume of 34.9652 million shares, and a turnover of HK$205 million. The company’s stock price has been “seven consecutive positives”, rising 99.34% since February 3. With the help of AI empowerment, the popularity of innovative drugs has not diminished. The Hong Kong Stock Innovative Drug ETF (159567) rose by 2.86% during the intraday session on February 27, and finally closed at 0.95%, with a turnover of 359 million yuan and a turnover rate of over 73%. Since hitting the bottom on January 13, the Hong Kong Stock Innovative Drug ETF has risen by 30.79%. Hang Seng Index Company recently announced the results of its regular quarterly index adjustments. This coincides with the semi-annual index review of the Hang Seng Composite Index, which will become the main basis ...
- Source: drugdu
- 121
- March 3, 2025
Hong Kong stocks have the highest growth rate in the world! The Hang Seng Index rose in February, close to the full year of 2024. The Hong Kong Stock Exchange made a net profit of 13 billion last year

On February 27, the Hong Kong Stock Exchange (00388.HK) (hereinafter referred to as “HKEX”) disclosed its full-year results for 2024, with full-year revenue and other income of HK$22.4 billion, a year-on-year increase of 9%; profit attributable to shareholders of HK$13 billion, a year-on-year increase of 10%. The Hong Kong Stock Exchange said that although the market conditions continued to fluctuate in 2024, the global economic outlook was relatively optimistic and the market atmosphere improved. This background is beneficial to the trading activities and performance of various markets under the Hong Kong Stock Exchange. In February this year, the Hong Kong stock market performed well, and investors talked about it with great enthusiasm. The Hang Seng Index rose to the top of the world’s major stock market indices. From the beginning of February to February 27, the Hang Seng Index has risen by 17.27%, which is basically the same as the ...
- Source: drugdu
- 147
- March 3, 2025
Children eating bats caused an epidemic. The “strange disease” in the Democratic Republic of the Congo has killed 60 people.

The World Health Organization said that an unexplained epidemic broke out simultaneously in five villages in the Equateur Province in the northwest of the Democratic Republic of the Congo, which has infected 1,100 people and killed 60 people. Most of the dead patients had only about 48 hours from the onset of symptoms to death. Ngashi Ngongo, an official of the Africa Centers for Disease Control and Prevention, said in an online briefing on February 27 that the test report showed that in the Basankusu medical area of Equateur Province, 309 (54.1%) of the 571 patients tested for malaria tested positive. Last year, another mysterious flu-like illness that killed dozens of people in another part of the country was eventually identified as malaria. At the same time, the malaria virus is currently spreading in the Equateur Province. But the WHO said that it has not yet been determined whether there ...
- Source: drugdu
- 121
- March 3, 2025
Tonghua Dongbao Liraglutide Injection Accepts GMP On-site Audit by the Egyptian Ministry of Health

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. and its partner Sinovac Biotech Co., Ltd. (hereinafter referred to as “Sinovac”) jointly launched the overseas product Liraglutide Injection, which received the GMP on-site audit by the Egyptian Ministry of Health. The audit was conducted at the company’s production base. The company and Sinovac Biotech collaborated efficiently and closely cooperated with the on-site inspection of the Egyptian Ministry of Health, which is currently progressing smoothly. Liraglutide, as a human glucagon-like peptide-1 (GLP-1) analog, can activate human GLP-1 receptors and promote pancreatic insulin secretion. In addition to effectively controlling blood sugar, it can also protect cardiovascular and reduce weight. The product has significant efficacy and high safety, and is widely recognized worldwide. https://finance.eastmoney.com/a/202502283332960051.html
- Source: drugdu
- 116
- March 3, 2025
1st and only one! 1 Medical Device Approved by FDA

Recently, Alcon, a global leader in ophthalmic healthcare, announced its innovative product, the Direct Selective Laser Trabectomy (DSLT) device – Voyager ™ DSLT has been approved by the FDA and will be fully launched in the United States. According to Alcon, this innovative product is the world’s first and currently the only direct selective laser trabeculoplasty device, which is expected to promote laser therapy as a first-line treatment for glaucoma and benefit more patients. Glaucoma potential device heavily approved Glaucoma is a group of eye diseases characterized by progressive damage to the optic nerve, and one of its important factors is the relative increase in intraocular pressure (IOP), which is an irreversible cause of blindness. As the primary cause of irreversible blindness, many patients do not realize their condition until their vision is lost, so early intervention (from medication to surgery) is crucial for protecting vision. At present, international authoritative ...
- Source: drugdu
- 150
- February 28, 2025
Revolutionizing Medical B2B Trade with AI-Powered Intelligence

I. How AI is Transforming the Medical B2B Industry? In the global pharmaceutical and medical device B2B trade landscape, businesses face numerous challenges, including information opacity, complex regulatory compliance, difficulty in tracking market trends, and cross-border communication barriers. As a leading B2B platform dedicated to the pharmaceutical and medical device industry, Drugdu.com (www.drugdu.com) provides global suppliers and buyers with a trusted marketplace for efficient sourcing and trade. To further enhance industry efficiency and optimize trade decision-making, Drugdu.com has officially launched Drugdu AI—a cutting-edge AI solution tailored for the pharmaceutical B2B sector. Powered by DeepSeek’s advanced AI technology, Drugdu AI leverages Drugdu.com’s extensive industry resources and global data to enable precise access to sector-specific insights, market trends, and compliance guidelines while paving the way for AI-driven trade decision-making in the future. II. What is Drugdu AI? 1. Drugdu AI is an AI-driven intelligent Q&A system developed by Drugdu.com, designed to provide pharmaceutical ...
- Source: drugdu
- 343
- February 28, 2025
Aimi Vaccines has been approved by the FDA to conduct clinical trials of mRNA vaccines

On February 27, Aimi Vaccines (06660) issued an announcement announcing that its mRNA respiratory syncytial virus vaccine has been approved by the U.S. Food and Drug Administration (FDA) for clinical trials. This is the first time that the company has obtained FDA approval for clinical trials, marking an important progress in its internationalization strategy. The announcement mentioned that in preclinical animal trials, the specific IgG antibody titer, true virus neutralizing antibody titer, and specific T cell immunity of the vaccine were significantly higher than those of the internationally marketed control vaccines, showing the competitiveness of its research and development results. Respiratory syncytial virus is an important pathogen that causes respiratory infections in infants and the elderly. At present, there is no approved antiviral specific drug for this virus in the world, so vaccination has become an effective means to prevent severe infection. As one of the earliest companies in China ...
- Source: drugdu
- 175
- February 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.